Cancer

SNIPR Biome receives funding for the development of CRISPR-medicines to improve Environmental Enteric Dysfunction (EED) in pregnant women

SNIPR BIOME receives funding from the Bill & Melinda Gates Foundation to accelerate the development of SNIPR Biome's microbial gene…

7 months ago

Nikon Introduces Newly Developed Imaging Technology for Greatly Accelerated Speed and Efficiency in Research for Biotechnology

MELVILLE, N.Y., June 27, 2024 /PRNewswire/ -- Nikon Instruments Inc. (Nikon) is expanding its AX series lineup with the introduction…

7 months ago

The Caris Precision Oncology Alliance Welcomes Leading Cancer Center

Caris expands its extensive network of leading cancer institutions committed to improving patient outcomes through innovations in precision medicine by…

7 months ago

Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering

CHATHAM, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated…

7 months ago

CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024

VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing…

7 months ago

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Leading women’s reproductive health conference directly follows the company’s EU CE Mark approval for four of its productsATLANTA, June 27,…

7 months ago

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

– Transaction aligns with Coherus’ strategic focus on oncology –REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences,…

7 months ago

Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights

Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues…

7 months ago

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing…

7 months ago